Early reduction of serum TARC levels may predict for success of ABVD as frontline treatment in patients with Hodgkin Lymphoma

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Background Many efforts have been made to predict prognosis of newly diagnosed Hodgkin Lymphoma (HL) patients. Objective of this study was to investigate the association between early reduction of Thymus and Activation-Regulated Chemokine after the first ABVD cycle (TARC-1) and prognosis of HL patients. Methods Serum samples of 116 HL patients were collected at baseline, after every ABVD cycle and during follow-up. The 99th centile of TARC distribution in a group of 156 independent healthy subjects (800 pg/ml) was considered as cut-off for discriminating between abnormal and normal TARC values. Findings 101 patients out of 116 had baseline TARC above 800 pg/ml (median value 27515 pg/ml (IQR, 11001‐68139)) and were the object of this analysis. TARC-1 significantly decreased to a median value of 556 pg/ml (IQR, 378–977 pg/ml). TARC-1 values below 800 pg/ml were associated with success of therapy (p = 0.0003) and PET-2 negativity (p = 0.001). TARC-1 ≤ 800 pg/ml identified a population with a significantly higher 5-years PFS in the whole cohort (90.1% vs 55.6%; p < 0.0001) and in both subgroups of advanced (p = 0.003) and early stage patients (p = 0.021). At multivariable analysis, TARC-1 was significant independent predictor of PFS (p = 0.0035). Interpretation Early reduction of TARC serum levels can predict success of treatment, being associated with achievement of interim PET-2 negative and favorable long-term outcome in HL patients receiving ABVD as front-line therapy.

Original languageEnglish
Pages (from-to)91-97
Number of pages7
JournalLeukemia Research
Volume62
DOIs
Publication statusPublished - Nov 1 2017

Fingerprint

Hodgkin Disease
Serum
Therapeutics
Chemokine CCL17
Healthy Volunteers
Reference Values
Population

Keywords

  • ABVD
  • Biomarker
  • Hodgkin
  • TARC

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

@article{d51dfaeddd534b8cb4a3d950d1ebd3c2,
title = "Early reduction of serum TARC levels may predict for success of ABVD as frontline treatment in patients with Hodgkin Lymphoma",
abstract = "Background Many efforts have been made to predict prognosis of newly diagnosed Hodgkin Lymphoma (HL) patients. Objective of this study was to investigate the association between early reduction of Thymus and Activation-Regulated Chemokine after the first ABVD cycle (TARC-1) and prognosis of HL patients. Methods Serum samples of 116 HL patients were collected at baseline, after every ABVD cycle and during follow-up. The 99th centile of TARC distribution in a group of 156 independent healthy subjects (800 pg/ml) was considered as cut-off for discriminating between abnormal and normal TARC values. Findings 101 patients out of 116 had baseline TARC above 800 pg/ml (median value 27515 pg/ml (IQR, 11001‐68139)) and were the object of this analysis. TARC-1 significantly decreased to a median value of 556 pg/ml (IQR, 378–977 pg/ml). TARC-1 values below 800 pg/ml were associated with success of therapy (p = 0.0003) and PET-2 negativity (p = 0.001). TARC-1 ≤ 800 pg/ml identified a population with a significantly higher 5-years PFS in the whole cohort (90.1{\%} vs 55.6{\%}; p < 0.0001) and in both subgroups of advanced (p = 0.003) and early stage patients (p = 0.021). At multivariable analysis, TARC-1 was significant independent predictor of PFS (p = 0.0035). Interpretation Early reduction of TARC serum levels can predict success of treatment, being associated with achievement of interim PET-2 negative and favorable long-term outcome in HL patients receiving ABVD as front-line therapy.",
keywords = "ABVD, Biomarker, Hodgkin, TARC",
author = "A. Guidetti and A. Mazzocchi and R. Miceli and E. Paterno and F. Taverna and F. Spina and F. Crippa and L. Farina and P. Corradini and Gianni, {A. M.} and S. Viviani",
year = "2017",
month = "11",
day = "1",
doi = "10.1016/j.leukres.2017.09.018",
language = "English",
volume = "62",
pages = "91--97",
journal = "Leukemia Research",
issn = "0145-2126",
publisher = "Elsevier Ltd",

}

TY - JOUR

T1 - Early reduction of serum TARC levels may predict for success of ABVD as frontline treatment in patients with Hodgkin Lymphoma

AU - Guidetti, A.

AU - Mazzocchi, A.

AU - Miceli, R.

AU - Paterno, E.

AU - Taverna, F.

AU - Spina, F.

AU - Crippa, F.

AU - Farina, L.

AU - Corradini, P.

AU - Gianni, A. M.

AU - Viviani, S.

PY - 2017/11/1

Y1 - 2017/11/1

N2 - Background Many efforts have been made to predict prognosis of newly diagnosed Hodgkin Lymphoma (HL) patients. Objective of this study was to investigate the association between early reduction of Thymus and Activation-Regulated Chemokine after the first ABVD cycle (TARC-1) and prognosis of HL patients. Methods Serum samples of 116 HL patients were collected at baseline, after every ABVD cycle and during follow-up. The 99th centile of TARC distribution in a group of 156 independent healthy subjects (800 pg/ml) was considered as cut-off for discriminating between abnormal and normal TARC values. Findings 101 patients out of 116 had baseline TARC above 800 pg/ml (median value 27515 pg/ml (IQR, 11001‐68139)) and were the object of this analysis. TARC-1 significantly decreased to a median value of 556 pg/ml (IQR, 378–977 pg/ml). TARC-1 values below 800 pg/ml were associated with success of therapy (p = 0.0003) and PET-2 negativity (p = 0.001). TARC-1 ≤ 800 pg/ml identified a population with a significantly higher 5-years PFS in the whole cohort (90.1% vs 55.6%; p < 0.0001) and in both subgroups of advanced (p = 0.003) and early stage patients (p = 0.021). At multivariable analysis, TARC-1 was significant independent predictor of PFS (p = 0.0035). Interpretation Early reduction of TARC serum levels can predict success of treatment, being associated with achievement of interim PET-2 negative and favorable long-term outcome in HL patients receiving ABVD as front-line therapy.

AB - Background Many efforts have been made to predict prognosis of newly diagnosed Hodgkin Lymphoma (HL) patients. Objective of this study was to investigate the association between early reduction of Thymus and Activation-Regulated Chemokine after the first ABVD cycle (TARC-1) and prognosis of HL patients. Methods Serum samples of 116 HL patients were collected at baseline, after every ABVD cycle and during follow-up. The 99th centile of TARC distribution in a group of 156 independent healthy subjects (800 pg/ml) was considered as cut-off for discriminating between abnormal and normal TARC values. Findings 101 patients out of 116 had baseline TARC above 800 pg/ml (median value 27515 pg/ml (IQR, 11001‐68139)) and were the object of this analysis. TARC-1 significantly decreased to a median value of 556 pg/ml (IQR, 378–977 pg/ml). TARC-1 values below 800 pg/ml were associated with success of therapy (p = 0.0003) and PET-2 negativity (p = 0.001). TARC-1 ≤ 800 pg/ml identified a population with a significantly higher 5-years PFS in the whole cohort (90.1% vs 55.6%; p < 0.0001) and in both subgroups of advanced (p = 0.003) and early stage patients (p = 0.021). At multivariable analysis, TARC-1 was significant independent predictor of PFS (p = 0.0035). Interpretation Early reduction of TARC serum levels can predict success of treatment, being associated with achievement of interim PET-2 negative and favorable long-term outcome in HL patients receiving ABVD as front-line therapy.

KW - ABVD

KW - Biomarker

KW - Hodgkin

KW - TARC

UR - http://www.scopus.com/inward/record.url?scp=85030713202&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85030713202&partnerID=8YFLogxK

U2 - 10.1016/j.leukres.2017.09.018

DO - 10.1016/j.leukres.2017.09.018

M3 - Article

VL - 62

SP - 91

EP - 97

JO - Leukemia Research

JF - Leukemia Research

SN - 0145-2126

ER -